[HIV infection and acquired immunodeficiency syndrome].
On June 4, 1981, MMWR published a report about Pneumocystis carinii pneumonia in homosexual men in Los Angeles. This was the first published report. A years later, this disease was named acquired immunodeficiency syndrome (AIDS). In the following year, Montangier et al in France discovered the causative agent, which they called lymphadenopathy virus (LAV), now known as human immunodeficiency virus (HIV). In 1985, solid-phase enzymeimmunoassay for the detection of the antibody to HIV was developed. Since then, other new techniques for the identification of HIV infection have been become available. These include more sensitive methods (for example; polymerase chain reaction techniques). Although these techniques facilitate early and definite diagnosis of infection, these tests may fail to detect the antibody in sera during window period of infection or overdiagnose infection in sera contaminated with genes not related to HIV. Although preventing blood exposure is the primary means of preventing occupationally acquired human immunodeficiency virus (HIV) infection, appropriate post-exposure management is an important element of workplace safety. Information suggesting that zidovudine (ZDV) postexposure prophylaxis (PEP) may reduce the risk for HIV transmission after occupational exposure to HIV infected blood prompted a Public Health Service (PHS) interagency working group, with expert consultation, and recommendations on PEP and management of occupational exposure to HIV in relation to these findings were discussed.
Takamatsu
J
J
Department of Transfusion Medicine, Nagoya University Hospital.
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis* / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000008:administration & dosage; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D015483:HIV Antibodies / Q000032:analysis; D015488:HIV Antigens / Q000032:analysis; D015658:HIV Infections / Q000175:diagnosis* / Q000517:prevention & control; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006281:Health Occupations; D006801:Humans; D008297:Male; D016273:Occupational Exposure; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis; D015215:Zidovudine / Q000008:administration & dosage
D019380:Anti-HIV Agents; D004279:DNA, Viral; D015483:HIV Antibodies; D015488:HIV Antigens; D012367:RNA, Viral; D015215:Zidovudine